Nicholas Hoffman & Company LLC. Buys 6,721 Shares of GSK plc (NYSE:GSK)

Nicholas Hoffman & Company LLC. increased its stake in shares of GSK plc (NYSE:GSK) by 16.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,176 shares of the pharmaceutical company’s stock after buying an additional 6,721 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in GSK were worth $1,595,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of GSK. Creative Planning grew its stake in shares of GSK by 3.9% in the 3rd quarter. Creative Planning now owns 211,100 shares of the pharmaceutical company’s stock worth $8,630,000 after acquiring an additional 7,854 shares in the last quarter. Blue Trust Inc. grew its position in GSK by 335.1% in the 3rd quarter. Blue Trust Inc. now owns 10,720 shares of the pharmaceutical company’s stock worth $413,000 after purchasing an additional 8,256 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of GSK by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after acquiring an additional 3,405 shares in the last quarter. Ledyard National Bank grew its holdings in shares of GSK by 24.1% in the third quarter. Ledyard National Bank now owns 24,281 shares of the pharmaceutical company’s stock valued at $993,000 after acquiring an additional 4,712 shares in the last quarter. Finally, Foundations Investment Advisors LLC grew its holdings in shares of GSK by 4.8% in the third quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock valued at $414,000 after acquiring an additional 466 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 1.0 %

NYSE GSK opened at $36.20 on Monday. The company has a market capitalization of $75.02 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.42 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The stock’s 50-day simple moving average is $34.42 and its two-hundred day simple moving average is $37.45.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts forecast that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.34%. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is 93.08%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.